Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takuma Kato

Showing results (171-180 of 190) with videos related to

Pageof 19
Sort By:
BJU International|June 18, 2024
Outcomes of active surveillance for Japanese patients with prostate cancer (PRIAS-JAPAN)Takuma Kato, Ryuji Matsumoto, Akira Yokomizo, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|April 8, 2025
Active Surveillance in Prostate Cancer With Intermediate-Risk Features: The PRIAS-JAPAN StudyLeandro Blas, Masaki Shiota, Takuma Kato, et al.
Urologic Oncology|June 11, 2021
Impact of health-related quality of life on repeat protocol biopsy compliance on active surveillance for favorable prostate cancer: results from a prospective cohort in the PRIAS-JAPAN studyYoichiro Tohi, Takuma Kato, Akira Yokomizo, et al.
International Journal of Clinical Oncology|August 10, 2020
The impact of complications after initial prostate biopsy on repeat protocol biopsy acceptance rate. Results from the Prostate Cancer Research International: Active Surveillance JAPAN studyYoichiro Tohi, Takuma Kato, Ryuji Matsumoto, et al.
International Journal of Clinical Oncology|February 28, 2024
Peripheral neuropathy and nerve electrophysiological changes with enfortumab vedotin in patients with advanced urothelial carcinoma: a prospective multicenter cohort studyRikiya Taoka, Masaki Kamada, Kazuyoshi Izumi, et al.
Japanese Journal of Clinical Oncology|June 6, 2022
Impact of adherence to criteria on oncological outcomes of radical prostatectomy in patients opting for active surveillance: data from the PRIAS-JAPAN studyYoichiro Tohi, Takuma Kato, Jimpei Miyakawa, et al.
Japanese Journal of Clinical Oncology|February 2, 2025
Validation of five prognostic models treated with axitinib beyond first-line nivolumab plus ipilimumab therapy for metastatic renal cell carcinoma: a Japanese multicenter retrospective studyHiroshi Kikuchi, Takahiro Osawa, Yuto Matsushita, et al.
World Journal of Gastroenterology|April 30, 2011
Thrombotic microangiopathy-like disorder after living-donor liver transplantation: a single-center experience in JapanTomohide Hori, Toshimi Kaido, Fumitaka Oike, et al.
Scientific Reports|July 3, 2024
PSA doubling time 4.65 months as an optimal cut-off of Japanese nonmetastatic castration-resistant prostate cancerShinichi Sakamoto, Kodai Sato, Takahiro Kimura, et al.
JNCI Cancer Spectrum|February 4, 2022
Clinical Utility of Germline Genetic Testing in Japanese Men Undergoing Prostate BiopsyShusuke Akamatsu, Naoki Terada, Ryo Takata, et al.
Pageof 19

Showing results (171-180 of 190) with videos related to

Sort By:
Pageof 19
BJU International|June 18, 2024
Outcomes of active surveillance for Japanese patients with prostate cancer (PRIAS-JAPAN)Takuma Kato, Ryuji Matsumoto, Akira Yokomizo, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|April 8, 2025
Active Surveillance in Prostate Cancer With Intermediate-Risk Features: The PRIAS-JAPAN StudyLeandro Blas, Masaki Shiota, Takuma Kato, et al.
Urologic Oncology|June 11, 2021
Impact of health-related quality of life on repeat protocol biopsy compliance on active surveillance for favorable prostate cancer: results from a prospective cohort in the PRIAS-JAPAN studyYoichiro Tohi, Takuma Kato, Akira Yokomizo, et al.
International Journal of Clinical Oncology|August 10, 2020
The impact of complications after initial prostate biopsy on repeat protocol biopsy acceptance rate. Results from the Prostate Cancer Research International: Active Surveillance JAPAN studyYoichiro Tohi, Takuma Kato, Ryuji Matsumoto, et al.
International Journal of Clinical Oncology|February 28, 2024
Peripheral neuropathy and nerve electrophysiological changes with enfortumab vedotin in patients with advanced urothelial carcinoma: a prospective multicenter cohort studyRikiya Taoka, Masaki Kamada, Kazuyoshi Izumi, et al.
Japanese Journal of Clinical Oncology|June 6, 2022
Impact of adherence to criteria on oncological outcomes of radical prostatectomy in patients opting for active surveillance: data from the PRIAS-JAPAN studyYoichiro Tohi, Takuma Kato, Jimpei Miyakawa, et al.
Japanese Journal of Clinical Oncology|February 2, 2025
Validation of five prognostic models treated with axitinib beyond first-line nivolumab plus ipilimumab therapy for metastatic renal cell carcinoma: a Japanese multicenter retrospective studyHiroshi Kikuchi, Takahiro Osawa, Yuto Matsushita, et al.
World Journal of Gastroenterology|April 30, 2011
Thrombotic microangiopathy-like disorder after living-donor liver transplantation: a single-center experience in JapanTomohide Hori, Toshimi Kaido, Fumitaka Oike, et al.
Scientific Reports|July 3, 2024
PSA doubling time 4.65 months as an optimal cut-off of Japanese nonmetastatic castration-resistant prostate cancerShinichi Sakamoto, Kodai Sato, Takahiro Kimura, et al.
JNCI Cancer Spectrum|February 4, 2022
Clinical Utility of Germline Genetic Testing in Japanese Men Undergoing Prostate BiopsyShusuke Akamatsu, Naoki Terada, Ryo Takata, et al.
Pageof 19